Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 4/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18796576 | 1.00 | LMNA (0.49) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL21302902 | 0.95 | LMNA (0.46) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL16781378 | 0.95 | LMNA (0.46) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL5491755 | 0.93 | LMNA (0.54) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL6882664 | 0.93 | LMNA (0.54) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL5491765 | 0.93 | LMNA (0.54) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL10527109 | 0.92 | LMNA (0.44) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL10424383 | 0.92 | LMNA (0.44) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL10424384 | 0.92 | LMNA (0.44) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL10424382 | 0.92 | LMNA (0.44) | LMNARAB9ASMN1; SMN2PKMFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352067-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | Research & Business Foundation Sungkyunkwan University (KR) | 2024-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352067-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | NOD2, SI, APC | LMNA 2698/4885RAB9A 1580/4885SMN1; SMN2 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.